Tampere University Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

  NCT07679269· Phase 2· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Not yet recruiting

  T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial)

  NCT07900620· Tampere University Hospital· Source

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source

• Not yet recruiting

  Randomized Clinical Trial for Tonsil Surgery in Adults With Obstructive Sleep Apnea and Enlarged Tonsils

  NCT07580170· Turku University Hospital· Source

• Not yet recruiting

  A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence

  2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source

• Recruiting

  A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL

  2025-524915-36-00· Phase 1/2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Thromboprophylaxis with Apixaban during neoadjuvant therapy for muscle-invasive Bladder cancer

  2024-518861-90-00· Phase 4· HUS-Yhtymae· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Recruiting

  OBE2026 - Effect of One Year Intensive Lifestyle Treatment in Children With ISO-BMI Over 30kg/m² and Their Families.

  NCT07738029· Tampere University Hospital· Source

• Not yet recruiting

  A clinical trial investigating Tranexamic Acid use in hind and midfoot arthrodesis surgery

  2026-526142-27-01· Phase 3· HUS-yhtymae· Source

• Recruiting

  Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive Disorder

  NCT07644130· Tampere University Hospital· Source

• Recruiting

  A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer

  NCT07594327· Tampere University Hospital· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

  NCT07027306· AO Foundation, AO Spine· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  ListenFuture-Listening for Their Future: Deaf and Hard-of-Hearing Adolescents

  NCT07416292· Heikki Löppönen· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer

  NCT07331519· Oulu University Hospital· Source

• Recruiting

  Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

  NCT07352800· Phase 2· Aplagon Oy· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Recruiting

  Histomolecular Profiling in Small-Bowel Diseases

  NCT07556328· Tampere University Hospital· Source

• Recruiting

  Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.

  NCT07430007· University of Eastern Finland· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Not yet recruiting

  Transmission of Oncogenic HPV Infection Among Families

  NCT07036211· Tampere University Hospital· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· AstraZeneca· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis

  NCT07665320· Tampere University· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation

  NCT06696079· Phase 2/3· Rahul Raj· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· Phase 3· University Of Cologne· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· AstraZeneca· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 170.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers15 recruiting
• Prostate cancer10 recruiting
• Colorectal cancer7 recruiting
• Endometrial cancer7 recruiting
• Lung cancer6 recruiting
• Acute myeloid leukaemia5 recruiting
• Atrial fibrillation4 recruiting
• Coeliac disease4 recruiting
• Deep vein thrombosis and pulmonary embolism4 recruiting
• Metastatic breast cancer4 recruiting
• Ovarian cancer4 recruiting
• Pancreatic cancer4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Bladder cancer3 recruiting
• Cervical cancer3 recruiting
• Crohn's disease3 recruiting
• Kidney cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Melanoma3 recruiting
• Osteoarthritis3 recruiting
• Stroke3 recruiting
• Chronic kidney disease2 recruiting
• Heart failure2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Obesity2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 1 diabetes2 recruiting
• Brain metastases1 recruiting
• Bronchiectasis1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Hearing loss1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Iron deficiency anaemia1 recruiting
• Multiple sclerosis1 recruiting
• Narcolepsy1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Peripheral artery disease1 recruiting
• Sarcoma1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Pfizer· Source

• Completed

  A Study of TAK-861 in People With Narcolepsy Type 1

  NCT06505031· Phase 3· Takeda· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Completed

  A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

  2023-506509-21-00· Phase 1· Verge Genomics· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

  NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Completed

  Evaluation of the MiniMed 780 System in Paediatric Subjects

  NCT05574062· Medtronic MiniMed, Inc.· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Completed

  Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP

  NCT05401201· Koite Health Oy· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source

• Active, not recruiting

  A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

  NCT05428969· Phase 1/2· Faron Pharmaceuticals Ltd· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  NCT05196035· Phase 3· Bayer· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Bristol Myers Squibb International Corporation· Source

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Pfizer· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source

• Terminated

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Phase 3· Hoffmann-La Roche· Source

• Completed

  Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis

  NCT04845074· University of Aarhus· Source

• Active, not recruiting

  A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

  NCT04810078· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab

  2023-503229-21-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  SAPIEN 3 Ultra EU PMS

  NCT04860752· Edwards Lifesciences· Source

• Completed

  Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

  NCT04725188· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Incyte Corporation· Source

• Terminated

  Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

  NCT04796324· Phase 2· Allarity Therapeutics· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

  NCT04597125· Phase 4· Bayer· Source

• Completed

  Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

  NCT04593251· Phase 1· Calypso Biotech BV· Source

• Completed

  A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

  NCT04530110· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Hoffmann-La Roche· Source

• Withdrawn

  Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

  NCT03806049· Phase 3· Nordic Society of Gynaecological Oncology - Clinical Trials Unit· Source

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia

  NCT03979014· Phase 3· Imperial College London· Source

• Completed

  A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for Inhalation" 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), Followed by a 2-Year Open-Label Extension

  NCT04204252· Phase 3· Kamada Ltd.· Source

• Completed

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· Phase 3· AstraZeneca· Source

• Completed

  Safety and Pharmacokinetics of ODM-209

  NCT03878823· Phase 1/2· Orion Corporation, Orion Pharma· Source

• Completed

  A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

  NCT03661320· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  Safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer

  2024-517439-39-00· Phase 1/2· Orion Corporation· Source

• Completed

  A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

  NCT03371017· Phase 3· Hoffmann-La Roche· Source

• Completed

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 57.

Conditions

Diseases this institution publishes on or runs trials for.

• Coeliac disease32 works · 7 trials
• Type 1 diabetes24 works · 4 trials